<DOC>
	<DOCNO>NCT02701348</DOCNO>
	<brief_summary>The purpose study monitor change cancer size woman breast cancer anti-hormone treatment use different type assessment include ultrasound scan ( US ) , shearwave elastography ( SWE ) magnetic resonance imaging ( MRI ) , assess corresponds change cancer biology .</brief_summary>
	<brief_title>Radiological Biological Tumoural Peri-tumoural Factors Neoadjuvant Endocrine-treated Breast Cancers</brief_title>
	<detailed_description>Background Endocrine resistance significant problem management breast cancer , increase evidence tumour microenvironment influential tumour growth disease resistance . The neoadjuvant setting provide excellent opportunity observe tumour response treatment vivo , allow development method monitor predict response treatment . Aims To assess potential radiological biological tumoural peri-tumoural biomarkers patient neoadjuvant endocrine treatment . Our hypothesis le response woman abnormal peri-tumoural stroma , tumours high monocarboxyl transporter ( MCT4 ) loss caveolin-1 stroma resistant endocrine treatment . Techniques Methodology Patients primary breast cancer receive neoadjuvant letrozole undergo radiological assessment digital mammogram , US include SWE , MRI . Core biopsy take diagnosis surgery tumour peri-tumoural stroma , assess biomarkers lysyl oxidase ( LOX ) , fibronectin , collagen , proliferation , MCT4 caveolin-1 . All data correlate peri-tumoural abnormality MRI SWE . Impact breast cancer research This study provide information ability SWE MRI predict detect endocrine resistance , correlate biological marker associate endocrine resistance . Identifying resistant tumour prevent unnecessary treatment reduce risk recurrence alternative additional therapy utilise .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal woman : Defined &gt; 12 month amenorrhoea absence medical therapy know induce ; bilateral oophorectomy ; last menses &lt; 12 month start treatment , FSH &gt; 35 IU/L LH &gt; 40 IU/L . ER positive ( Allred score &gt; 3 ) invasive breast cancer Staging T14 , N02 , M0 Patient agree neoadjuvant endocrine therapy recommend MDT Fresh tissue store time diagnostic core biopsy Suitable , tolerant MRI scan Fit surgical intervention time entry study Premenopausal unable determine menopausal status Not fit surgical intervention due comorbidities Contraindication MRI ( include severe claustrophobia ) Current use HRT , HRT use time diagnostic core biopsy</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>neoadjuvant endocrine</keyword>
</DOC>